about
The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine DerivativesSynthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition processNovel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry.Fluorescent ligands for adenosine receptors.Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility.Human A3 adenosine receptor as versatile G protein-coupled receptor example to validate the receptor homology modeling technology.Receptor-driven identification of novel human A₃ adenosine receptor antagonists as potential therapeutic agents.The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands.Advances in Computational Techniques to Study GPCR-Ligand Recognition.Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists.The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationRevisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists.A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approach.Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites.Impact of protein-ligand solvation and desolvation on transition state thermodynamic properties of adenosine A2A ligand binding kinetics.Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.Discovery of simplified N²-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: efficient synthetic approaches, biological evaluations and molecular docking studies.8-(2-Furyl)adenine derivatives as A₂A adenosine receptor ligands.Exploring the directionality of 5-substitutions in a new series of 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a strategy to design novel human a(3) adenosine receptor antagonists.Does the combination of optimal substitutions at the C²-, N⁵- and N⁸-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A₃ adenosine receptors?A2A Adenosine Receptor Antagonists as Therapeutic Candidates: are they still an interesting challenge?Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists.[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A3 adenosine receptor subtype5,7-Disubstituted-[1,2,4]triazolo[1,5- a ][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptorsScaffold Decoration at Positions 5 and 8 of 1,2,4-Triazolo[1,5-c]Pyrimidines to Explore the Antagonist Profiling on Adenosine Receptors: A Preliminary Structure–Activity Relationship StudyTargeting protein kinase CK1δ with Riluzole: could it be one of the possible missing bricks to interpret its effect in the treatment of ALS from a molecular point of view?A facile and novel synthesis of N2-, C6-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonistsA Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic InhibitionConjugable A3 adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probesFunctionalized ligands targeting G protein-coupled adenosine receptorsThe current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapyPyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines to develop functionalized ligands to target adenosine receptors: fluorescent ligands as an example
P50
Q28551225-3C1E2561-7AB5-4EA5-B977-CBCDF6BD43FDQ35020369-6DFD3D93-1AC4-4486-8689-DDDA72B66BAAQ35877911-74107498-3E2F-4F4D-AF4F-6CE2966D8D1FQ36570374-A5B0477C-1C03-4DFD-8CDC-033246C00672Q36626953-F53B4AAF-48A4-4AD9-B6BB-0E501D28A765Q37661082-A6579CCE-DE77-4160-8B0D-4C8B7D2999EDQ37807135-ADCDE7A8-FB28-4B03-BE52-2C27543283E7Q37957791-AEE3FE60-A69B-4038-BDED-B6A342B038B8Q37995704-164D641D-2F85-4B64-A72B-085E4E7C48B6Q38625628-59354011-40C6-49DE-BCAA-F515A9E5B73AQ38826846-7272A733-4A88-4194-985A-C5748253BFCFQ43122244-6E2599DB-A325-43A8-B4AB-FF07E59F4FB3Q44616497-BDD37615-EB60-4E11-BFEC-3E34CF392025Q45821403-313D588F-892C-4E10-AAE2-C5B3F520851EQ45980337-C97454FB-3F45-459F-8F48-030CCAEC0A8AQ47225761-15C1EDA6-35DB-4C4A-A74D-5BCDB6199284Q47568155-4A95F961-219F-4583-9D5F-B574F4250F3DQ51750136-1275244D-443A-45D6-8D9E-98BDED89D6E9Q51751278-7D815678-9A62-41A7-A704-3EB97EFAC223Q51756244-406315C8-398D-463F-8E0A-FAAEDB788D7BQ51765407-EC336944-072A-4039-BFEE-7E762EE56D87Q52564955-6EC12BA2-149A-4234-998C-133E98A9CA47Q53804425-A0A90DD1-220F-4082-8F4F-866C82A0F60AQ56979411-F02BDEAB-9CA7-4ADF-A45A-1794DFC7EF24Q56979458-3A11DE4F-29EB-4FE9-B553-6436EBC90353Q56979507-9E6012AD-501A-45B1-8194-66F91704297DQ57785102-B1E681E2-D3A3-4187-BCEF-55A244551E70Q61050737-82AF04D9-A813-4D82-9CFA-D21968AC179BQ64788264-F3E54D26-BEA6-4D4C-B614-BBF825082135Q91579782-AC218DCE-1039-4CC8-B04E-190EE6FB740CQ91981276-A6F52C68-56E1-4BA6-8CAC-DF4B31D02683Q92131082-9C8D5510-BEF2-4B76-818C-510315631C1BQ92485727-4F82E8A5-4B7E-46AE-97B9-17E6337D48EA
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stephanie Federico
@ast
Stephanie Federico
@en
Stephanie Federico
@es
Stephanie Federico
@nl
Stephanie Federico
@sl
type
label
Stephanie Federico
@ast
Stephanie Federico
@en
Stephanie Federico
@es
Stephanie Federico
@nl
Stephanie Federico
@sl
prefLabel
Stephanie Federico
@ast
Stephanie Federico
@en
Stephanie Federico
@es
Stephanie Federico
@nl
Stephanie Federico
@sl
P1053
E-8496-2018
P106
P1153
35101716200
P21
P31
P496
0000-0003-2800-5287